Eroziant
Eroziant Uses, Dosage, Side Effects, Food Interaction and all others data.
An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Debrisoquin is an adrenergic neuron-blocking drug similar in effects to guanethidine. It is a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
| Trade Name | Eroziant |
| Generic | Debrisoquine |
| Debrisoquine Other Names | Debrisochinum, Debrisoquin, Debrisoquina, Debrisoquine, Débrisoquine, Debrisoquinum |
| Weight | 125mg |
| Type | Suspension |
| Formula | C10H13N3 |
| Weight | Average: 175.2303 Monoisotopic: 175.110947431 |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | Eros Pharmaceuticals |
| Available Country | Pakistan |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
For the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.
How Eroziant works
Debrisoquin acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine, rather than acting at the effector cell by inhibiting the association of norepinephrine with its receptors. It is taken up by norepinephrine transporters. It becomes concentrated in NE transmitter vesicles, replacing NE in these vesicles. This leads to a gradual depletion of NE stores in the nerve endings. Once inside the terminal it blocks the release of noradrenaline in response to arrival of an action potential. In contrast to ganglionic blocking agents, debrisoquin suppresses equally the responses mediated by alpha-and beta-adrenergic receptors but does not produce parasympathetic blockade. Since sympathetic blockade results in modest decreases in peripheral resistance and cardiac output, debrisoquin lowers blood pressure in the supine position. It further reduces blood pressure by decreasing the degree of vasoconstriction that normally results from reflex sympathetic nervous activity upon assumption of the upright posture, thus reducing venous return and cardiac output more.
Food Interaction
- Take with or without food. The absorption is unaffected by food.
Innovators Monograph
You find simplified version here Eroziant
